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Context: Patients with thyroidal congenital hypothyroidism (CH-T)
born in The Netherlands in 1981–1982 showed persistent intellectual
and motor deficits during childhood and adulthood, despite initiation
of T4 supplementation at a median age of 28 d after birth.
Objective: The present study examined whether advancement of
treatment initiation to 20 d had resulted in improved cognitive and
motor outcome.
Design/Setting/Patients: In 82 Dutch CH-T patients, born in 1992
to 1993 and treated at a median age of 20 d (mean, 22 d; range, 2–73
d), cognitive and motor outcome was assessed (mean age, 10.5 yr;
range, 9.6–11.4 yr). Severity of CH-T was classified according to
pretreatment free T4 concentration.
MainOutcomeMeasure:Cognitive andmotor outcome of the 1992–
1993 cohort in comparison to the 1981 to 1982 cohort was the main
outcome measure.
Results:Patientswith severe CH-T had lower full-scale (93.7), verbal
(94.9), and performance (93.9) IQ scores than the normative popula-
tion (P 0.05), whereas IQ scores of patients with moderate andmild
CH-T were comparable to those of the normative population. In all
three severity subgroups, significant motor problems were observed,
most pronounced in the severe CH-T group. No correlations were
found between starting day of treatment and IQ or motor outcome.
Conclusions: Essentially, findings from the 1992–1993 cohort were
similar to those of the 1981–1982 cohort. Apparently, advancing ini-
tiation of T4 supplementation from 28 to 20 d after birth did not result
in improved cognitive or motor outcome in CH-T patients. (J Clin
Endocrinol Metab 92: 919–924, 2007)
IN CONGENITAL HYPOTHYROIDISM (CH), thyroidhormone deficiency is present from the prenatal period
onward until, after birth, adequate T4 supplementation is
provided. Because the period of thyroid hormone deficiency
coincides with a critical period of brain development, chil-
dren with CH, if left untreated, are at risk for impaired brain
development and subsequent cognitive and motor deficits.
The aim of neonatal CH screening programs is to prevent
cerebral damage through early initiation of T4 supplemen-
tation, which shortens the period of postnatal hypothyroid-
ism. In a previous nationwide study we followed patients
with thyroidal CH (CH-T) born in 1981–1982, the first years
of the Dutch screening. We found persistent subtle cognitive
and motor deficits up to adulthood in these patients, for
whom T4 supplementation was initiated at a median age of
28 d after birth (1, 2). In 1981–1982, initial treatment strategy
and starting day of treatment differed from current practice,
which is characterized by treatment initiation at a younger
age, with higher initial T4 doses. Several studies evaluating
themore recent practice have shown improved cognitive and
motor outcome (3–6). However, due to small sample sizes
and the relatively young age of the children, it is still unclear
whether postnatal T4 supplementation is capable of estab-
lishing completely normal intellectual, motor, and socioemo-
tional development in patients with CH-T (7).
The Dutch screening procedure has been adapted several
times since its introduction in 1981. One of themajor changes
is the advancement of the heel puncture sampling from 6–14
d initially to 6–8 d in the early 1990s and to d 4 from 1999
onward. This change in timing of the heel puncture sampling
enabled us to investigate whether earlier treatment initiation
had resulted in improved cognitive and motor outcome. We
investigated cognitive and motor outcome at 10.5 yr of age
in a nationwide cohort of CH patients born in 1992–1993, in
whom treatment was initiated at a median age of 20 d.
Outcomewas analyzed in relation to etiology and severity of
CH and in relation to treatment variables. Furthermore, the
results of the present study were compared with those ob-
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tained from patients born and screened in 1981–1982, exam-
ined at the age of 9.9 yr of age, in whom T4 supplementation
was initiated significantly later (1).
Subjects and Methods
Screening method and treatment strategy
The Dutch neonatal CH screening method is primarily based on the
measurement of T4 in filter paper blood spots. In 1992–1993, sampling
was performed between 6 and 8 d after birth. T4, expressed as sd score,
is compared with the day mean. If T4 was 0.8 sd or less, TSH was
additionally measured. When T4 was 3.0 sd or less or TSH was 50
U/ml or more, children were referred immediately. Children with a
dubious result [3.0 T42.1 sd, or 28 TSH50 U/ml (in 1992)
or 20 TSH 50 (in 1993)] underwent a second heel puncture andwere
referred if the result was again dubious or abnormal. The etiological
classification of CH was based on thyroid function determinants and
thyroid imaging.
In 1992–1993, Dutch pediatricians were advised to start with 6–8 g
T4/kgd. In accordance with international guidelines, T4 dose adjust-
ments were based on thyroid function determinants, obtained at regular
outpatient follow-up visits.
Patients of the 1992–1993 cohort
The institutional review board of the Emma Children’s Hospital
Academic Medical Center (AMC) and the privacy committee of the CH
Screening Board approved the study protocol. The Netherlands Orga-
nization of Applied Scientific Research (TNO) documents the screening
results and diagnostic findings of all children screened for CH in The
Netherlands.
For the majority of children referred because of an abnormal CH
screening result, blood and/or urine samples are sent to the AMC; for
each patient, a record is made. Combination of the records (TNO and
AMC) revealed that the complete cohort of CH patients born in The
Netherlands in 1992–1993 consisted of 141 patients (Table 1). Of them,
three had died, four had moved abroad, and four had transient CH. The
parents of the remaining 130 patients were approached by their pedi-
atricians, whose responses led to the exclusion of patients with a known
or suspected syndrome (n  12), exceptionally late start of treatment
(n  3, initiation of treatment  300 d after birth), (treatment for) brain
tumor (n  1), blindness (n  1), encephalopathy after hypoxia (n  2),
or hypoglycemia (n  1); and patients of whom the mother was treated
with T4 during pregnancy (n  2) (Table 1, “not suitable”). The parents
of 18 patients refused participation (Table 1, “not willing”).
To ascertain that the participating patients were euthyroid (i.e. TSH
0.4–4.0 U/ml) at the time of testing, the most recent measurement of
thyroid function before the psychological tests was evaluated and, if
necessary, T4 dose was adjusted. This resulted in dose adjustments for
20 patients. Because of misunderstandings, the recommended dose ad-
justments were not made in time in three patients who were excluded
from the analysis (Table 1, “not suitable”).
Of the 87 participating patients (62% of the original cohort), 82 had
CH-T, and five had central CH (CH-C). The test results of patients with
CH-C are presented separately, because of difference in etiology and
treatment; all of them received besides T4 supplementation, cortisol, and
GH. Patients with CH-T were classified to subgroups based on their
pretreatment free T4 (FT4) concentration: severe CH, initial FT4  0.3
ng/dl (4 pmol/liter); moderate CH, 0.3 initial FT4 0.6 ng/dl (4.0
initial FT4  8.0 pmol/liter); or mild CH, initial FT4  0.6 ng/dl (8.0
pmol/liter). FT4 reference range for children aged 2–6 wk was 0.9–2.2
ng/dl (12–28 pmol/liter) (8).
Assessments
Cognitive and motor assessments were performed in the AMC (ex-
cept for seven patients who were tested in their local hospitals) by the
same psychologist, who was blinded for the patient’s medical details.
Patients were tested at a mean age of 10.5 yr (range, 9.6–11.4 yr).
Cognitive assessments
Intelligence was assessed with the Dutch version of the Wechsler
Intelligence Scale for Children, third edition (WISC-III) (9), except for the
first 10 patients who were tested with the WISC-R (10) because the
WISC-III was not yet available. With the subjects’ performance on 10
subtests, three IQ scores were derived: full-scale IQ (FSIQ); verbal IQ
(VIQ); and performance IQ (PIQ). In the normative population, each IQ
score has a mean of 100 (sd 15). The scores of the WISC-R were recal-
culated intoWISC-III scores in accordance with the guidelines provided
in the WISC-III manual (9, 11).
Motor assessments
Motor skills were assessed with the Movement Assessment Battery
for Children (MABC) (12, 13), designed for identification of impairments
ofmotor function in children aged 4–12 yr. The test results are expressed
in terms of a total motor impairment score (range, 0 to 40; mean, 5.0 in
the normative population; in the text referred to as total MABC score),
a manual dexterity score (0–15), a ball skills score (0–10), and a balance
score (0–15); higher scores indicate more motor problems. In the nor-
mative population, 85% have no motor problems (total MABC score 
9.5), 10% have borderline motor problems (9.5  total MABC score 
13.5), and 5% have definite motor problems (total MABC score  13.5).
Patients of the 1981–1982 cohort
Data of 58 patientswith CH-T born in 1981–1982 (43% of a total cohort
of 136 CH patients) who were studied at a mean age of 9.9 yr (range,
9.0–10.9 yr) (1) were available for retrospective analysis. IQ was mea-
sured with the WISC-R (10). Motor skills were tested with the Test of
TABLE 1. Etiology of CH in the 1992–1993 cohort
Etiology Totalgroup Participants
Nonparticipants
Not willing Not suitable
Thyroid agenesis 24 17 1 6 (moved abroad, 1; syndrome, 1; syndrome suspected, 2;
T4 dose not adequate, 2)
Thyroid dysgenesis 51 48 1 2 (T4 dose not adequate, 1; euthyroid without T4 supple-
mentation, 1)
Thyroid dyshormonogenesis 24 17 4 3 (syndrome, 1; mother treated with T4 during preg-
nancy, 2)
CH-T not otherwise specified 26 11 15 (moved abroad, 3; patient died, 3; euthyroid without
T4 supplementation, 3; syndrome, 5; tumor, 1)
CH-C 16 5 1 10 (blindness, 1; encephalopathy, 3; syndrome suspected,
3; late initiation of treatment, 3)
Total 141 87 18 36
Three groups are presented: the total group, the group of participating patients (with either CH-T or CH-C), and the group of nonparticipants,
either because patients were considered not suitable (with the reason specified in parentheses) or because parents were not willing. The number
of patients in each etiological classification subgroup is given for each group.
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Motor Impairment (TOMI) (14). The TOMI later evolved into theMABC,
and both contain comparable items. The total motor impairment score
(referred to in the text as total TOMI score) ranges from 0 to 20; higher
scores indicate more motor problems. In the normative population, 85%
have no motor problems (total TOMI score  4), 10% have borderline
motor problems (4 total TOMI score 6), and 5% have definite motor
problems (total TOMI score  6).
Statistical analysis
Comparisons of IQ and motor scores were made between the fol-
lowing subgroups: severe vs.moderate vs.mild CH-T and early-treated
vs. late-treated patients with severe, moderate, or mild CH-T (i.e. before
or after the mean starting day of treatment). FSIQ scores and the per-
centage of patientswithmotor problems of the 1992–1993 and 1981–1982
cohorts were compared.
One-sample t tests were used to determine whether the IQ scores in
the total CH-T group and the severity subgroups differed from the norm
of 100. Binomial tests were conducted to test whether the percentage of
CH-T patients in the severity subgroups that had a motor score more
than 9.5 differed from the percentage in the normative population.
ANOVA was used for group comparisons on continuous variables;
post hoc group comparisons were performed with Bonferroni post hoc
analysis. 2 tests were used for categorical variables. For variables in
which the distributions of scores differed significantly from the normal
distribution, nonparametric tests such as the Mann-Whitney U tests
were used. Linear regressionmodels were fitted for IQ andmotor scores
with severity (initial T4 concentration) and starting day of treatment as
independent variables. In addition, bivariate correlation analyses be-
tween severity of CH-T, starting day of treatment, or initial T4 dose, and
IQ or motor scores were performed and between FSIQ and total MABC
score. It was not necessary to correct for parental educational level, a
potential confounder, because this appeared to be distributed equally
over the subgroups: parental educational level by severity (2  1.260;
P  0.868) and parental educational level by early or late treatment (2
 2.435; P  0.296).
Results
Patients with CH-T
Characteristics of the participants are given in Table 2. Of
the 82 patients with CH-T (53 girls, 65%), 50% had severe
CH-T, of whom the majority had thyroid agenesis (39%) or
dysgenesis (39%), and 50% had moderate or mild CH-T, of
whom themajority had thyroid dysgenesis (78%). In patients
with severe and moderate CH-T, the mean age at initiation
of T4 supplementation was younger than in patients with
mild CH-T. The median age at initiation of T4 supplemen-
tation for the total CH-T group was 20 d (mean, 22 d).
Intellectual and motor outcome
Mean FSIQ, VIQ, and PIQ scores of the total CH-T group
were not significantly different from the population means
(Table 3). Themean total MABC score was subnormal for the
total CH-T group and significantly different from the mean
of the normative population (P  0.001; Table 4).
Mean FSIQ, VIQ, and PIQ scores in the severe CH-T group
differed significantly from the population means (P 0.004,
P  0.039, P  0.003, respectively; Table 3), whereas in the
moderate and mild CH-T group mean IQ scores were not
significantly different from the population means. In the
severe CH-T group, FSIQ and PIQ scores were significantly
lower than in the mild CH-T group (P  0.007, P  0.005,
respectively; Table 3).
The mean total MABC scores in the severe, moderate, and
mild CH-T subgroups were significantly different from the
mean of the normative population (P 0.001, P 0.003, P
0.001, respectively; Table 4). Patients with severe CH-T had
significantly worse scores on total MABC and manual dex-
terity than patients with moderate CH-T (P  0.023, P 
0.004, respectively; Table 4). The percentages of patients in
the severe, moderate, and mild CH-T subgroups, with a
subnormal total MABC score (70, 37, and 59%, respectively)
were significantly higher than in the normative population
(P 0.001, P 0.016, P 0.001, respectively). The difference
between severe and moderate CH-T in percentages of pa-
tients with a subnormal total MABC score was significant
(P  0.023).
In the severe CH-T group, IQ and motor scores did not
differ in patients treated less than 19 d after birth vs. patients
treated 19 d ormore after birth. IQ andmotor scoreswere not
different in the moderate and mild CH-T group when treat-
ment was initiated before or after 19 and 31 d, respectively.
In a multiple regression analysis with severity of CH-T
(expressed as the initial plasma FT4 concentration) and start-
ing day of treatment as independent variables, only the se-
verity of CH-T appeared to be a significant predictor of FSIQ
(Table 5).
In a bivariate correlation analysis, the initial FT4 concen-
tration appeared to be associated with FSIQ (r  0.298; P 
0.015), PIQ (r  0.314; P  0.010), and manual dexterity (r 
TABLE 2. Characteristics of the participants
Severe CH-T Moderate CH-T Mild CH-T CH-C
No. of patients (male:female) 41 (13:28) 19 (6:13) 22 (10:12) 5 (4:1)
Initial FT4 (ng/dl) (range)a
pmol/liter (range)
0.1 (0.0–0.3) 0.4 (0.3–0.6) 1.0 (0.7–1.6) 0.6 (0.4–0.7)
1.8 (0.0–4.0) 5.6 (4.2–7.1) 12.8 (9.0–20.2) 7.7 (5.4–9.6)
Initial TSH (U/ml) (range)b 693 (254–1500) 493 (163–760) 120 (28–502) 4 (2–5)
Total defectsc
Agenesis 16 1
Dyshormonogenesis 7
Partial defectsc
Dysgenesis 16 17 15
Dyshormonogenesis 2 1 7
Age at start of T4
supplementation (d) (range)
19 (10–43) 19 (9–41) 31 (2–73) 34 (14–58)
Initial T4 dose (g/kgd) (range) 7.0 (3.2–12.9) 6.6 (4.0–10.3) 5.0 (2.8–9.0) 8.1 (4.2–11.1)
Initial plasma FT4 and TSH concentrations, the age at start of treatment, and the initial T4 dose are expressed as mean (range).
a Reference range for FT4 in children aged 2 to 6 wk, 0.9–2.2 ng/dl, 12–28 pmol/liter (8).
b Reference range for TSH in children aged 2 to 6 wk, 1.7–9.1 U/m (8).
c Only for patients with CH-T.
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0.247; P  0.047). No correlation was found between start-
ing day and IQ or motor scores; nor was there a correlation
between initial T4 dose and IQ or motor scores. Also within
the severe CH-T group, starting day of treatment or initial T4
dose did not correlate with IQ or motor scores.
FSIQ and total MABC score were not significantly corre-
lated (r  0.204; P  0.073).
Comparison of the 1992–1993 and 1981–1982 cohorts
Mean FSIQ and the percentage of patients with motor
problems of patients born in 1992–1993 and in 1981–1982
with severe,moderate, andmild CH-T are presented in Table
6. In patients with severe and mild CH-T, the age at start of
T4 supplementation was significantly different between the
1981–1982 cohort and the 1992–1993 cohort (P  0.001, P 
0.003, respectively), but not in patients with moderate CH-T
(P  0.087). The initial T4 dose of patients in the severity
subgroups was not significantly different between the 1981–
1982 and the 1992–1993 cohort (P 0.086,P 0.938,P 0.248
for severe, moderate, and mild CH-T, respectively). FSIQ
scores of the severity subgroups were not significantly dif-
ferent between the two cohorts. In patients with mild CH-T,
the percentage of patients with a subnormal total motor
impairment score was higher in the 1992–1993 cohort than in
the 1981–1982 cohort (P  0.013); for severe and moderate
CH-T, differences were not significant.
Patients with CH-C
The five patients with CH-C (four boys) had a mean initial
FT4 concentration between that of patients with moderate
and mild CH-T (Table 2); none of the CH-C patients had an
initial FT4 concentration less than 0.3 ng/dl (4 pmol/liter).
T4 supplementation was initiated at a mean age of 34 d after
birth. Patients with CH-C had a mean FSIQ of 99.0 (range,
92.5–105.5); meanVIQwas 96.6 andmean PIQwas 102.2. The
mean manual dexterity score was 8.4, ball skills 1.2, and
balance 4.9. The mean total MABC score (14.5) was substan-
tially higher than themean of the normative population (5.0),
four of the five patients had a subnormal score (i.e. 9.5).
Discussion
The present study analyzed cognitive andmotor outcome in
a Dutch cohort of 10-yr-old children with early treated CH. IQ
scores for the total CH-T group, in whom treatment was ini-
tiated at a median age of 20 d, were not significantly different
from the normative population. Within the subgroup of severe
CH-T patients, however, cognitive outcomewas less favorable.
With regard to motor skills, the total CH-T group had substan-
tial motor problems, which were slightly more pronounced in
severe CH-T patients. Severity of CH-T correlated significantly
with FSIQ, PIQ, and manual dexterity score. No correlation,
however, was found between the starting day of treatment
(median, 20 d; range, 2–73 d) or initial T4 dose (range, 2.8–12.9
g/kgd) and IQ or motor scores.
The current findings are in line with our recent observa-
tions of persistent cognitive andmotor deficits in adultDutch
CH-T patients, born in 1981–1982, in whom treatment was
initiated at a median age of 28 d (range, 4–293 d). Also in the
1981–1982 cohort, severity of CH-T was an important pre-
dictor of long-term outcome, but not timing of treatment
initiation (2). Over the course of the first decade after intro-
duction of the nationwide CH screening, treatment initiation
for CH patients was substantially advanced; patients with
severe CH-T born in 1981–1982were treated from amean age
of 29 d (median, 29 d), whereas those born in 1992–1993 were
treated from a mean age of 19 d (median, 17 d). Apparently,
this advancement did not result in an improvement in in-
tellectual development. It is conceivable that also in the 1992–
1993 cohort the time frame for a preventive effect of early
treatment initiation had elapsed, as was previously sup-
posed for the 1981–1982 cohort (2). Alternatively, (irrevers-
ible) brain damage in severe CH might have accrued in the
TABLE 3. IQ scores of the CH-T group
FSIQ P (t) Verbal IQ P (t) Performance IQ P (t)
Severe CH-T (n  41) 93.7 (89.5–97.9)a,c 0.004 (3.0) 94.9 (90.1–99.7)b 0.039 (2.1) 93.9 (90.0–97.8)a,c 0.003 (3.1)
Moderate CH-T (n  19) 96.2 (88.9–103.5) 0.290 (1.1) 95.4 (87.9–102.9) 0.210 (1.3) 98.0 (91.1–104.9) 0.550 (0.6)
Mild CH-T (n  22) 105.0 (99.5–110.4) 0.073 (1.9) 103.6 (98.2–109.1) 0.182 (1.4) 105.3 (99.3–111.3) 0.082 (1.8)
Total (n  82) 97.3 (94.2–100.4) 0.088 (1.7) 97.4 (94.1–100.6) 0.113 (1.6) 97.9 (94.8–100.9) 0.172 (1.4)
Range 57–129 65–138 58–134
IQ scores, expressed as mean (confidence interval), are presented for the total CH-T group and the three severity subgroups. P values (with
t value in parentheses) refer to the comparison with the normative population.
a P  0.01 compared to the population mean.
b P  0.05 compared to the population mean.
c P  0.01 compared to mild CH-T.
TABLE 4. Motor scores of the CH-T group
Total MABC score Manual dexterity Ball skills Balance
Severe CH-T (n  41) 14.37 (11.8–16.8)a,c 8.2 (7.0–9.5)b 2.4 (1.5–3.3) 4.1 (3.2–5.0)
Moderate CH-T (n  19) 9.7 (6.8–12.5)a 5.1 (3.5–6.6) 1.6 (0.6–2.6) 3.0 (1.9–4.1)
Mild CH-T (n  22) 11.6 (8.7–14.6)a 6.0 (4.1–7.8) 1.6 (0.7–2.6) 4.0 (2.7–5.4)
Total (n  82) 12.4 (10.8–14.0)a 6.8 (6.0–7.7) 2.0 (1.4–2.6) 3.8 (3.2–4.5)
Motor scores, expressed as mean (confidence interval), are presented for the total CH-T group and the three severity subgroups.
a P  0.01 compared to the normative population.
b P  0.01 compared to moderate CH-T.
c P  0.05 compared to moderate CH-T.
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prenatal period. The importance of the in utero thyroid hor-
mone state has been illustrated by the fact that maternal
hypothyroidism during pregnancy is known to result in cog-
nitive andmotor deficits in the offspring (15).One has to keep
in mind that CH is already expressed in fetal life and that
maternal T4, transferred via the placenta, is not sufficient to
fill the gap in fetal T4 production.
The conviction prevailing in the prescreening era that early
treatment would prevent mental retardation has led to the
introduction of neonatal screening once the appropriate tech-
niques (Guthrie card and radioimmunoassays) became avail-
able. However, a series of follow-up studies on the cohortswho
were originally screened showed that children still had persis-
tent subtle deficits, despite early treatment (1, 2). Several studies
have investigated the possible benefits of advancing the initi-
ation of T4 supplementation on outcome in CH patients de-
tected by neonatal screening. As in our study, Boileau et al. (16)
investigated the impact of changes in the screening procedure
over a 15-yr period: IQ scores of CH patients in whom T4
supplementationwas initiated before 21 d after birthwere sim-
ilar to controls, whereas IQ scores of patients treated after this
age were significantly lower. This study, however, did not
investigate outcome of patients with severe CH as a subgroup.
Dubuis et al. and Simoneau-Roy et al. have shown that intel-
lectual outcome in patientswith severeCH, inwhom treatment
was initiated at amedian age of 14 dwith amean initial T4 dose
of 12.1 g/kgd, was normal both at 18 months (3) and 5 yr of
age (17). Their patient groups, however, were rather small (n
8 and 9, respectively). In a sample of Dutch CH patients born
between 1993 and 1996, Bongers-Schokking et al. (4) have
shown that in severe CH, a treatment delay of 6 d, in patients
receiving an initial T4 dose of 10.8 g/kgd, led to a loss of 25
points on theMentalDevelopmental Indexof theDutchversion
of the Bayley Scales of Infant Development, when measured
between11and30monthsof age.Remarkably, retestingat 5.5–7
yr of agegave contrasting results: a treatmentdelayof 7d resulted
in a small increase of 3.6 IQ points (5). No distinction was made
according to severity of CH because of small group size.
Towhat extent the initial T4 dose is a key factor in preserving
optimal brain development in CH patients is unclear (18); even
recent reports about this issue gave contradictory results. Selva
et al. (6), considering a mean initial T4 dose of 10.9 g/kgd as
relatively low, found that patients with CH, receiving this dose
at a mean postnatal age of 10.9 d, had lower FSIQ scores than
controls (89.7 vs. 100.2). However, Bongers-Schokking and de
Muinck Keizer-Schrama (5), considering a similar dose of 10.6
g/kgd, as relatively high, found that patients with CH, re-
ceiving this dose at amean postnatal age of 10.8 d, scored equal
to controls (104.6 vs. 105.0 Rakit IQ score). Any effect of both
initial and long-term T4 supplementation on cerebral develop-
TABLE 5. Multiple regression analysis for IQ and motor scores
FSIQ Verbal IQ Performance IQ Total MABC Manual dexterity Ball skills Balance
Initial plasma FT4
concentration
B 0.816 0.760 0.753 0.202 0.121 0.082 0.023
 0.296 0.277 0.262 0.142 0.156 0.156 0.039
P 0.034 0.051 0.057 0.324 0.276 0.268 0.786
Starting day of T4
supplementation
B 0.005 0.110 0.124 0.062 0.018 0.017 0.036
 0.005 0.101 0.110 0.110 0.060 0.084 0.156
P 0.973 0.470 0.420 0.443 0.674 0.549 0.276
R2 adjusted 0.060 0.030 0.080 0.015 0.006 0.014 0.000
Model significance F(2,63)  3.077,
P  0.053
F(2,63)  2.014,
P  0.142
F(2,63)  3.817,
P  0.027
F(2,60)  1.471,
P  0.238
F(2,62)  1.179,
P  0.314
F(2,63)  1.457,
P  0.241
F(2,62)  1.008,
P  0.371
Results of multiple regression analysis are given with initial plasma FT4 concentration and starting day of T4 supplementation as
independent variables and IQ scores and motor scores as dependent variables.
TABLE 6. FSIQ scores and percentages of CH-T patients with motor problems born in 1992–1993 and 1981–1982
FSIQ score Percentage of patients with motor problems
CH-T group
1992–1993
CH-T group
1981–1982
CH-T group
1992–1993
CH-T group
1981–1982
Age (yr) 10.5 9.9 10.5 9.9
Severe CH-T n  41a and 27b 93.7 (89.5–97.9) 94.3 (87.9–100.8) 71 52
Age at start of T4 supplementation (d) 19 29 19 29
Initial T4 dose (g/kgd) 7.0 5.4 7.0 5.4
Moderate CH-T (n  19a and 17b) 96.2 (88.9–103.5) 98.9 (91.6–106.3) 37 41
Age at start of T4 supplementation (d) 19 27 19 27
Initial T4 dose (g/kgd) 6.6 7.4 6.6 7.4
Mild CH-T (n  22a and 14b) 105.0 (99.5–110.4) 98.7 (89.2–108.2) 59 15
Age at start of T4 supplementation (d) 31 68 31 68
Initial T4 dose (g/kgd) 5.0 5.2 5.0 5.2
Total group 97.3 (94.2–100.4) 96.8 (92.7–100.9) 60 40
FSIQ, expressed as mean (confidence interval), and percentages of patients with a subnormal MABC (i.e. 9.5, 15% in the normative
population) or TOMI (i.e. 4, 15% in the normative population) score are presented, as well as the number of patients, the mean age at start
of T4 supplementation, and the mean initial T4 dose for each severity subgroup and the total group.
a Number of patients for each severity subgroup in the 1992–1993 cohort.
b Number of patients for each severity subgroup in the 1981–1982 cohort.
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ment is ultimately mediated by the intracellular thyroid hor-
mone receptor occupation, established via the plasma FT4 con-
centration. Consequently, establishing adequate plasma FT4
concentrations as soon as possible after initiation of T4 supple-
mentation and themaintenance of adequate FT4 concentrations
thereafter are considered important factors determining out-
come of CH patients. However, in a previous study we could
not demonstrate a solid correlation between the height of the
initial T4 dose and the time needed to reach a plasma FT4
concentration within the reference range (19). This probably
explainswhywecouldnot findacorrelationbetween theheight
of the initial T4 dose and outcome.
A limitation of the current study is thatmotor performance
in both CH cohorts had to be assessed with slightly different
test methods, as they evolved over time. The MABC, used in
the 1992–1993 cohort, contains test items comparable to the
TOMI, used in the 1981–1982 cohort, but is considered more
sensitive because items are scored on a six-point instead of
a three-point scale and because a larger reference group is
used (12, 14). Therefore, although it may seem that motor
outcome in the 1992–1993 cohort is worse in comparison to
the 1981–1982 cohort, this effect may be the consequence of
the higher sensitivity of the MABC.
An advantage of the current study is that the design pro-
vided the opportunity to study the influence of substantially
advanced treatment initiation by comparing data of two
large nationwide recruited cohorts of CH patients. In fact,
age at treatment initiation was the only variable that essen-
tially distinguished the two cohorts.
Finally, this is the first report on developmental outcome of
patients with central CH detected by neonatal screening. The
challenge in this group is timely and adequate multiple hor-
monal supplementations to establish normal growth and brain
development, and, especially, to prevent hypoglycemia. The
percentage of CH-C patients considered not suitable to partic-
ipate was relatively high, inherent to their (syndromal) condi-
tion of multiple pituitary hormone deficiencies. However, the
results of the participating patients are encouraging in that
timely andadequate hormonal supplementation established IQ
and motor scores not different from patients with moderate
CH-T.
In conclusion, this study has shown substantial cognitive
andmotor deficits in patients with severe CH-T, whose treat-
ment with T4 was initiated at a mean age of 19 d after birth.
Mildly and moderately affected CH-T patients had a fair
prognosis for IQ, but they too experienced motor problems.
Despite a substantially advanced treatment initiation, as
spinoff of a decade of experience with neonatal screening,
improvement of cognitive or motor outcome failed to occur.
Although it is possible that with further advancement of
treatment initiation or adaptations in T4 dose intellectual and
motor deficits will disappear, the observed deficits might
also be the consequence of the prenatal hypothyroid state.
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